Of the steps involved in the killing of Escherichia coli by colicins, binding to a specific outer-membrane receptor was the best understood and earliest characterized. Receptor binding was believed to be an indispensable step in colicin intoxication, coming before the less well-understood step of translocation across the outer membrane to present the killing domain to its target. In the process of identifying the translocator for colicin Ia, I created chimaeric colicins, as well as a deletion missing the entire receptorbinding domain of colicin Ia. The normal pathway for colicin Ia killing was shown to require two copies of Cir: one that serves as the primary receptor and a second copy that serves as translocator. The novel Ia colicins retain the ability to kill E. coli, even in the absence of receptor binding, as long as they can translocate via their Cir translocator. Experiments to determine whether colicin M uses a second copy of its receptor, FhuA, as its translocator were hampered by precipitation of colicin M chimaeras in inclusion bodies. Nevertheless, I show that receptor binding can be bypassed for killing, as long as a translocation pathway is maintained for colicin M. These experiments suggest that colicin M, unlike colicin Ia, may normally use a single copy of FhuA as both its receptor and its translocator. Colicin E1 can kill in the absence of receptor binding, using translocation through TolC.
Introduction
Colicins have been classified by the high-affinity outermembrane receptors they have cannibalized as a means to attach to the cells they kill [1, 2] . Those receptors are, in most instances, TonB-dependent transporters whose normal role in the life of bacteria is to bind essential small molecules, such as siderophore-bound iron or vitamins [3] . For example, the E colicins and colicin A initially bind to the vitamin B 12 receptor BtuB, and colicins B and D use FepA, the ferric enterobactin receptor, for their initial attachment to the cell surface. Bacteria with mutations in the receptor are resistant to killing by high concentrations of that particular colicin [4] . A characteristic of resistant mutants is that they can no longer absorb the specific colicin, and outer-membrane extracts from resistant cells cannot serve to protect sensitive cells from that particular colicin, unlike extracts from cells with functional receptors. The central domain of colicins was shown, first by genetic mapping and deletion analysis, and subsequently by molecular cloning and X-ray crystallography, to be responsible for binding to the receptors [5] [6] [7] .
After receptor binding, a step in intoxication called translocation requires both the N-terminal portion of the colicin molecule and one of two groups of Escherichia coli periplasmic and inner-membrane-anchored proteins to provide the energy required for cell entry. These are the TolA, TolB, TolQ and TolR proteins, used by Group A Key words: colicin, outer membrane, periplasm, receptor binding, translocator. Abbreviations used: C domain, catalytic domain; R domain, receptor domain; T domain, translocation domain. 1 email karen.jakes@einstein.yu.edu colicins, or TonB, ExbB and ExbD proteins used by Group B or TonB-dependent colicins [8] . Sequences in the colicins' translocation domains, called the TolA box, TolB box or TonB box, interact near the outer membrane in the periplasm to connect the colicin to its Tol-or TonB-dependent innermembrane energy source, in processes that have begun to be dissected in the last few years [4, 9, 10] .
Between the steps of receptor binding and Tol-or TonBdriven uptake, the colicin must move or begin to move from its tightly bound seat on its receptor through a translocator, some sort of passageway through the outer membrane, so that its N-terminus can interact with the periplasmic translocation machinery. It is this step of colicin intoxication that is the focus of the present short review and the subject of some recent experiments I describe. I discuss several examples where high-affinity binding of colicin to its outer-membrane receptor, although greatly increasing the efficiency of killing, is not absolutely required for killing by some colicins, whereas passage through the outer-membrane translocator invariably is. In other words, translocation trumps receptor binding.
The E. coli outer-membrane proteins used by colicins for binding to the cell surface are members of a family of 22-stranded β-barrel proteins whose N-terminal ∼160 residues form a plug that completely occludes the barrel domain [3] . These transporters all have a TonB box, a short sequence near their N-terminus, which binds specific sequences on TonB in the periplasm [11, 12] . Until X-ray crystal structures of colicin R (receptor) domains bound to their cognate receptors were solved [7, 13] , it was possible to fantasize about a mechanism in which binding of the colicin to the receptor would cause the plug to rearrange and move out of the way, thus allowing an unfolded colicin to pass through the barrel of the receptor. But faced with the reality of structures in which there was little or no movement of the plug when the colicin bound, another model was needed. In the case of the Tol-dependent colicins, there was an obvious answer. The trimeric porin OmpF had been demonstrated to be somehow involved in the uptake of colicins A, E2 and E3 [5] and was therefore called a 'second receptor'; channels formed in planar lipid bilayer membranes by OmpF were occluded by colicin E3 [7] . A model was therefore proposed [7] whereby colicin E3 (and other enzymatic E colicins) binds via its R domain to its BtuB, with its translocation (T) and catalytic (C) domains extending at a 45
• angle out over the outer membrane. That arrangement, coupled with the largely unstructured nature of the N-termini of the colicins and the long coiled-coil (>100 Å ; 1 Å = 0.1 nm) separating the R domain from the T and C domains [14] allows the T domain to search, or 'fish', for a nearby copy of OmpF, into which the T domain inserts to initiate translocation of the colicin across the outer membrane. This model was confirmed by crystallization of segments of the colicin E3 and E9 T domains within the OmpF pore [15, 16] . Similarly, TolC is required for killing by colicin E1 and is occluded by that colicin in planar lipid bilayer membranes [17] . This supports the idea that the colicin moves through the large channel that TolC forms [18] , which extends from the outer membrane across the periplasm, and thereby delivers the channel-forming colicin near its inner-membrane target.
No 'second receptors' had ever been identified for TonBdependent colicins, which include colicins Ia, Ib, M, B and D [4] . All of these colicins have a short sequence near their N-termini called the TonB box. Mutation of either the TonB box of the colicin or the TonB box of the receptor impairs killing by the colicin. Compensatory mutations in the TonB protein can restore colicin activity [13, 19] , implying two separate interactions of TonB, one with the receptor's TonB box and a second with the colicin's TonB box. (This is different from the situation with Tol-dependent colicins, which use TonB-dependent transporters as their primary receptors, but do not need a functional TonB box on the receptor for killing activity [20] ). It was therefore suggested that TonB-dependent colicins such as colicin Ia may use two separate copies of their receptor for intoxication: one serving as the primary high-affinity receptor and a second serving as the translocator, playing a role such as OmpF or TolC does for the Tol-dependent colicins.
To test that possibility, Jakes and Finkelstein [21] constructed a hybrid colicin in which the colicin Ia R domain had been replaced by the colicin E3 R domain [14] . Remarkably, the chimaera had a specific activity identical with that of wild-type colicin E3 when tested for killing activity on a wild-type indicator strain. As predicted, the new colicin required the E3 receptor BtuB for full activity; on a btuB mutant, its activity was reduced 1000-fold, or 10 000-fold less than wild-type colicin Ia on a wild-type indicator. But, like colicin Ia, the hybrid also still required the colicin Ia receptor Cir for activity; on a cir mutant, neither Ia nor the hybrid had any activity, even though the hybrid uses BtuB as its receptor. Both proteins also absolutely require TonB for activity (Table 1) . Thus, for the hybrid colicin, Cir appears to be playing a role distinct from that of primary receptor. Somewhat surprisingly, although activity of the hybrid colicin on a btuB mutant was substantially reduced, there was still significant residual killing, suggesting that this new colicin was bypassing a receptor to access the target cells. In fact, deleting the entire R domain from colicin Ia resulted in a protein with the same specific killing activity on either wild-type cells or btuB − cells, but again with no activity at all on a cir deletion. Since the isolated channelforming domain of colicin Ia has no killing activity on bacterial cells (although it makes voltage-dependent channels on planar lipid bilayer membranes), killing by the R domain deletion must be initiated by an interaction of the T domain with the Cir protein. Such an interaction was confirmed by cloning and purifying the 225-residue colicin Ia T domain and demonstrating that the T domain, when added to sensitive E. coli, can protect them from killing by colicin Ia, presumably by binding to Cir and blocking binding and/or translocation of the colicin [21] . The binding of the T domain must be relatively weak, since large molar excesses must be used to accomplish protection. The TonB box of colicin Ia is not involved in the T domain binding that protects cells from challenge by intact colicin Ia; the 64-residue unstructured N-terminus of the T domain is necessary, but not sufficient, for the binding to Cir [21] . Taken together, these experiments confirmed the idea that Cir is playing two distinct roles in colicin Ia cell killing, both that of primary outer-membrane receptor and also as the translocator. A model for how colicin Ia binds and translocates using Cir is shown in Figure 1 . Since there is still significant killing in the absence of any receptor-binding domain, in the R domain deletion mutant or in the hybrid when interacting with a btuB mutant, translocation appears to 'trump' receptor binding. As long as the translocator is present and functional, the colicin can kill cells, albeit with greatly reduced activity.
In order to try to determine whether other TonBdependent colicins share the translocation mechanism of colicin Ia, using two copies of the receptor protein, one for tight binding of the colicin's R domain and a second as the translocator, hybrid colicins were constructed with colicin M. Colicin M is quite different from colicin Ia in a number of important ways. It uses the ferrichrome receptor FhuA as its primary outer-membrane receptor; it is an enzyme that inhibits cell wall synthesis and leads to cell lysis, by degrading undecaprenyl phosphate-linked peptidoglycan precursors [22, 23] ; and it is only approximately one-third the size of colicin Ia, with a much more compact structure and a T domain of approximately 37 residues [24] , rather than the 225-residue T domain of colicin Ia [25] . Its domains had been carefully defined by structure-function studies [24, 26, 27] . Despite the rather profound differences with colicin Ia, I attempted to make a hybrid protein in which the 135-residue Table 1 Killing activity of various colicins and colicin constructs on E. coli indicator lawns Ten-fold dilutions of the colicins (1 mg/ml) were spotted on lawns of the strains shown. All activities are shown as the inverse of the last dilution at which there is a visible spot. Designations refer to the source of a particular domain: Ia-E3R is colicin Ia with the R domain of colicin E3; Ia R is Ia with the R domain deleted; M-E3R is colicin M with the E3 R domain; IaT-MRC is colicin M with its T domain replaced by that of colicin Ia; E1 R is colicin E1 with its R domain deleted. R domain of colicin E3 [14] replaced the central receptorbinding domain of colicin M, from residues 38 to 120. Although this construct was robustly expressed, none was found in the soluble fraction of producing bacteria; it was all in inclusion bodies. Several other similar constructs using slightly different insertion points in colicin M also yielded insoluble hybrid proteins. Dissolving the inclusion body in 8 M urea and then renaturing by dilution and dialysis and subsequent concentration and purification by nickel chromatography yielded a small amount of pure soluble protein that had no detectable in vivo killing activity. There is evidence that at least the E3 R domain was correctly folded, since it inhibits killing by active colicin E3; making dilutions of active colicin E3 in the inactive ME3R hybrid and then spotting on sensitive E. coli lawns reduced the activity of the colicin E3 by over two orders of magnitude relative to dilutions made in buffer, suggesting that the colicin M hybrid was binding BtuB and protecting the sensitive cells from colicin E3 (Table 1) . These experiments are insufficient to say whether or not colicin M uses a second copy of its FhuA as its translocator. There is, however, another experiment that suggests that perhaps colicin M translocates differently than colicin Ia. When colicin Ia is added to cultures of growing, sensitive E. coli at concentrations of approximately 170 molecules per molecule of Cir, there is very little killing of the culture. Lowering the colicin concentration 100-fold results in complete inhibition of cell growth [21] (Figure 2a ). This result can be explained if the higher concentration leads to every copy of Cir being occupied by colicin Ia tightly bound, via its R domain, thus leaving no copies of Cir unoccupied to serve as translocators through which the colicin can actually enter the cell. Performing a similar experiment with colicin M, however, gives a very different result (K.S. Jakes, unpublished work) (Figure 2b) . Even under conditions that should reduce the number of copies of the colicin M receptor FhuA [28] , very high concentrations of colicin M inhibit growth as well as much lower concentrations. This result alone argues against the idea that colicin M uses two copies of its FhuA protein for binding and translocation.
It is possible that the much smaller size and shorter T domain of colicin M make a 'fishing pole' mechanism of searching for a remote translocator impossible. In its size, colicin M is similar to colicin N, a Tol-dependent channelforming colicin that is also much smaller than the E colicins. It is unique in that it uses OmpF as both its receptor and its translocator [29] . However, OmpF is a trimer, with three separate pores [30] . It is therefore possible to envisage a mechanism whereby colicin N binds via its R domain to one pore, allowing its T domain to then begin translocation, either via another pore in the same trimer or, as suggested by recent experiments of Lakey and co-workers, down the outside of OmpF through the protein-lipid interface [31, 32] . Such a mechanism, in which the R domain of colicin M binds FhuA and then its T domain could move through the outer membrane at the FhuA-lipid interface, would be attractive for colicin M, but cannot explain either the requirement for a functional TonB box on FhuA or the requirement for the colicin's interaction with TonB for full activity [33] . On the basis of the limited experimental evidence described in the present paper, the mechanism of translocation of colicin M remains unclear.
Although it is not yet clear whether or not colicin M translocates through FhuA, either via the same copy to which it initially binds or to another copy of the same protein, it is possible for that colicin to be translocated via a different translocator. A hybrid colicin, in which the 37-residue T domain of colicin M [24] was replaced by the 225-residue colicin Ia T domain, was expressed and purified as a soluble protein. That protein has in vivo killing activity on wildtype E. coli, but, unlike colicin M, does not require FhuA for killing (Table 1) . Killing by the hybrid IaT-MRC protein is slightly more than two orders of magnitude less than that of colicin M on wild-type cells and is further reduced only slightly on a fhuA mutant on which colicin M is completely inactive. However, the new colicin absolutely requires a functional Cir protein, unlike colicin M, which does not use Cir (Table 1) . These results once again confirm that, even in the absence of a functional receptor, colicins can kill E. coli if they possess a translocation domain for which there is an accessible translocator; translocation trumps receptor binding. Once again, we see that receptor binding serves only to make killing orders of magnitude more efficient, by concentrating the colicin at the cell surface, so that it can search for its translocator in two dimensions, rather than in three.
Colicin E1 provides a third example of a colicin's ability to bypass receptor binding, as long as a relatively efficiently bound translocator is present. Colicin E1, unlike colicins Ia and M, is a Tol-dependent colicin and uses BtuB as its receptor. Uniquely among the E colicins, it requires TolC [34, 35] for killing. TolC is a homotrimeric 'channel tunnel' that extends from the outer membrane across the periplasm to near the inner membrane [18] , where colicin E1 makes channels that kill susceptible cells. TolC channels in planar Colicin Ia (a) or colicin M (b) was added in the amounts shown to exponentially growing cultures of sensitive E. coli and attenuances ('OD') were read at intervals (absorbance units, A.U.). Note that for colicin Ia, the higher colicin concentration, 15 μg/ml, caused very little killing, whereas 100-fold less colicin Ia killed very efficiently. For colicin M, both very high and much lower colicin concentrations exhibited very efficient killing.
lipid bilayer membranes were occluded by E1, as OmpF was by colicin E3, identifying TolC as the translocator for E1 [17] . Also uniquely among the E colicins, E1 does not require the periplasmic TolB protein, presumably because TolC delivers the colicin across the periplasm, bypassing a requirement for an intermediary between the translocator and TolA, a role played by TolB for the enzymatic E colicins that use OmpF as their translocator [36, 37] . Deleting either the entire receptor-binding domain from the colicin or BtuB from target cells still leaves significant E1 killing activity (Table 1) . Just as colicin Ia retained significant killing activity when its R domain was deleted [21] (Table 1) , the R domain deletion of colicin E1 also has significant activity, but has no measurable killing activity on a tolC deletion mutant, which lacks the translocator. Interestingly, on a btuB − mutant, the R domain deletion had 10-fold more specific killing activity than did full-length colicin E1 (Table 1) . A plausible explanation is that deleting the 147-residue R domain (residues 191-337) [38] makes translocation through TolC much more efficient than translocating the much longer intact colicin, and that step is the only one that must occur before either colicin engages the rest of the Tol translocation machinery, since there is no receptor-binding step in the absence of a functional BtuB. Thus this provides another example of translocation trumping receptor binding. In the cases described, where efficient binding of a colicin to a receptor at the cell surface has been eliminated, killing activity is reduced by at least two orders of magnitude, but if a functional translocator is present, there is still significant cell killing. This situation does not apply to the enzymatic E colicins, which have been shown to require BtuB, TolA, TolB and an energy source for uptake and release of their tightly bound immunity protein [39, 40] . None of the examples described in which there is significant killing in the absence of receptor binding includes a colicin that first sees its target as a heterodimer with its cognate immunity protein, which includes all of the nuclease colicins.
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